In pursuit of new developments for gene therapy of human diseases

Journal of Biotechnology

Volumn 68, Issue 1, 1999, Pages 1-13

  Palù, Giorgio ^a   Bonaguro, Roberta ^a   Marcello, Alessandro ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Disease; Gene therapy; Hereditary genetic disorders

Indexed keywords

CELLS; DISEASES; PATIENT TREATMENT;

GENE THERAPY;

GENE TRANSFER;

ADENOVIRUS; CANCER; CLINICAL TRIAL; DEGENERATIVE DISEASE; EXPRESSION VECTOR; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMATIC CELL; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC DISEASES, INBORN; GENETIC VECTORS; HUMANS; NEOPLASMS; VIRUSES;

ADENOVIRIDAE;

EID: 0033047205     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1656(98)00134-5     Document Type: Review

References (71)

1. Aebisher P., Schluep M., Deglon N., Joseph J.M., Hirt L., Heyd B.et al. Intrathecal delivery of CNTF using encapsulated, genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat. Med. 2:1996;696-699.
2. Ahn K., Angulo A., Ghazal P., Peterson P.A., Yang Y., Fruh K. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc. Natl. Acad. Sci. USA. 93:1996;10990-10995.
3. Arbuthnot P., Bralet M.P., Thomassin H., Danan J.L., Brechot C., Ferry N. Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by α-fetoprotein but not insulinlike growth factor II regulatory sequences. Hepatology. 22:1995;1788-1796.
4. Arbuthnot P.B., Bralet M.P., Lejossic C., Dedieu J.F., Perricaudet M., Brechot C., Ferry N. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum. Gene Ther. 7:1996;1503-1514.
5. - SCID: initial trial results after 4 years. Science. 270:1995;475-480.
6. Chen H., Mack L.M., Kelly R., Ontell M., Kochanek S., Clemens P.R. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc. Natl. Acad. Sci. USA. 94:1997;1645-1650.
7. Chu T.T.-H., Martinez I., Sheary W.C., Dornburg R. Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene Ther. 1:1994;292-299.
8. Chu T.T.-H., Dornbur R. Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer. J. Virol. 69:1995;2659-2663.
9. Cosset F.-L., Russell S.J. Targeting retrovirus entry. Gene Ther. 3:1996;946-956.
10. Cosset, F.-L., Takeuchi, Y., Battini, J.-L., Weiss, R.A., Collins, M.R.K., 1995a. High-titre packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 69, 7430-7436.
11. Cosset, F.-L., Morling, F.J., Takeuchi, Y., Weiss, R.A., Collins, M.K.L., Russell, S.J., 1995b. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J. Virol. 69, 6314-6322.
12. Dai Y., Schwarz E.M., Gu D., Zhang W., Sarvetnick N., Verma I.M. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA. 92:1995;1401-1405.
13. DiMaio J.M., Clary B.M., Via D.F., Coveney E., Pappas T.N., Lyerly H.K. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery. 116:1994;205-213.
14. Einerhand M.P.W., Antoniou M., Zolotikhin S., Muzyczka N., Berns K.I., Grosveld F., Valerio D. Regulated high-level human β-globin expression in erythroid cells following recombinant adeno-associated virus-mediated gene transfer. Gene Ther. 2:1995;336-343.
15. Engelhardt J.F., Ye X., Doranz B., Wilson J.M. Ablation of EA2 in recombinant retroviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA. 91:1994;6196-6200.
16. Feng M., Jackson W.H., Goldman C.K., Rancourt C., Wang M., Dusing S.K., Siegal G., Curiel D.T. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nature Biotech. 15:1997;866-870.
17. Ferrari G., Salvatori G., Rossi C., Cossu G., Mavilio F. A retroviral vector containing a muscle-specific enhancer drives gene expression only in differentiated muscle fibers. Hum. Gene Ther. 6:1995;733-742.
18. Feuerbach D., Burgert H.G. Novel proteins associated with MHC class I antigens in cells expressing the adenovirus protein E 3/19 k. EMBO J. 12:1993;3153-3161.
19. Fink D.J., Glorioso J.C. Engineering herpes simplex virus vectors for gene transfer to neurons. Nat. Med. 3:1997;357-359.
20. Ficker J. Fanconi's anemia, cord blood transplant and gene therapy. Mol. Med. Today. 2:1996;406-407.
21. Fruh K., Ahn K., Djaballah H., Sempe P., van Endert P.M., Tampe R., Peterson P.A., Yang Y. A viral inhibitor of peptide transporters for antigen presentation. Nature. 375:1995;415-418.
22. Gilbert M.J., Riddell S.R., Plachter B., Greenberg P.D. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature. 383:1996;720-722.
23. Gooding L.R. Virus proteins that counteracts host immune defenses. Cell. 71:1992;5-7.
24. Jones T.R., Wiertz E.J.H.J., Sun L., Fish K.N., Nelson J.A., Ploegh H.L. Human cytomegalovirus US 3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc. Natl. Acad. Sci. USA. 93:1996;11327-11333.
25. Han X., Kasahara N., Kan Y.W. Ligand-directed retroviral targeting of human breast cancer cells. Proc. Natl. Acad. Sci. USA. 92:1995;9747-9751.
26. Harson R., Grose C. Egress of varicella-zoster virus from melanoma cell; a tropism for the melanocyte. J. Virol. 69:1995;4994-5010.
27. Hauck W., Stanners C.P. Transcriptional regulation of the carcinoembryonic antigen gene. J. Biol. Chem. 270:1995;3602-3610.
28. Hill A., Jugovic P., York I., Russ G., Bennink J., Yewdell J., Ploegh H., Johnson D. Herpes virus turns off the TAP to evade host immunity. Nature. 375:1995;411-415.
29. Ho D.Y., Mocarski E.S. Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse. Proc. Natl. Acad. Sci. USA. 86:1989;7596-7600.
30. Ido A., Nakata K., Kato Y., Nakao K., Murata K., Fujita M., Ishii N., Tamaoki T., Shiku H., Nagataki S. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human α-fetoprotein gene promoter. Cancer Res. 55:1995;3105-3109.
31. Ilan Y., Droguett G., Chowdhury N., Li Y., Sengupta K., Thummala N.R., Davidson A., Chowdhury J.R., Horwitz M.S. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc. Natl. Acad. Sci. USA. 94:1997;2587-2595.
32. Kanai F., Shiratori Y., Yoshida Y., Wakimoto H., Hamada H., Kanegae Y.et al. Gene therapy for α-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex thymidine kinase gene. Hepatology. 23:1996;1359-1368.
33. Kaneko S., Hallembeck P., Kotani T., Nakabayashi H., McGarrity G., Tamaoki T., Anderson W.F., Chiang Y.L. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 55:1995;5283-5287.
34. Kasahara, N., Dozy, A.M., Kan, Y.W., 1994. Tissue-specific targeting of retroviral vectors through ligand-receptor interaction. Science 266, 1373-1376.
35. Lachmann R.H., Efstathiou S. Utilization of the herpes simplex virus type 1 latency associated regulatory region to drive stable reporter gene expression in the nervous system. J. Virol. 71:1997;3197-3207.
36. Lee C.-H., Liu M., Sie K.L., Lee M.-S. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-a and topoisomerase IIa in prostate cancer. Anticancer Res. 16:1996;1805-1812.
37. Lehner P.J., Kartunen J.T., Wilkinson G.W.G., Cresswell P. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc. Natl. Acad. Sci. USA. 94:1997;6904-6909.
38. Malik P., Krall W.J., Yu X.J., Zhou C., Kohn D.B. Retroviral-mediated gene expression in human myelomonocytic cells: a comparison of hematopoietic cell promoters to viral promoters. Blood. 86(8):1995;2993-3005.
39. Manca F., Fenoglio D., Franchin E., Saverino D., Li Pira G., Buffa F., Bignardi D., Del Pup L., Palù G. Anti-HIV genetic treatment of antigen-specific CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS. Gene Ther. 4:1997;1216-1224.
40. Miyoshi H., Takahashi M., Gage F.H., Verma I.M. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. USA. 94:1997;10319-10323.
41. Morishita K., Johnson D.E., Williams L.T. A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression. J. Biol. Chem. 270:1995;27948-27953.
42. Naldini, L., Blömer, U., Gage, F.H., Trono, D., Verma, I.M., 1996a. Efficient transfer, integration, and sustained long term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA 93, 11382-11388.
43. Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F.H., Verma, I.M., Trono, D., 1996b. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267.
44. Nilson B.H.K., Morling F.J., Cosset F.-L., Russell S.J. Targeting of retroviral vectors through protease-substrate interactions. Gene Ther. 3:1996;280-286.
45. Osaki T., Tanio Y., Tachibana I., Hosoe S., Kumagai T., Kawase I., Oikawa S., Kishimoto T. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell-type specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 54:1994;5258-5261.
46. Palù G. Combined strategies for gene therapy of AIDS. Gene Ther. 4:1997;179-180.
47. Parolin C., Dorfman T., Palù G., Gottlinger H., Sodroski J. Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes. J. Virol. 68:1994;3888-3895.
48. Parolin C., Taddeo B., Palù G., Sodroski J. Use of cis- and trans-acting viral regulatory sequences to improve expression of human immunodeficiency virus vectors in human lymphocytes. Virology. 222:1996;415-422.
49. Paulus W., Baur I., Boyce F.M., Breakefield X.O., Reeves S.A. Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J. Virol. 70:1996;62-67.
50. Peng K.W., Morling F.J., Murphy G., Russell S.J. A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum. Gene Ther. 8(6):1997;729-738.
51. Pizzato, M., Franchin, E., Calvi, P., Boschetto, R., Ferrini, S., Colombo, M., Palù, G., 1998. Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex thymidine kinase for gene therapy of cancer. Gene Ther. 5, 1003-1007.
52. Raper S.E., Grossman M., Rader D.J., Thoene J.G., Clark B.J., Kolansky D.M., Muller D.W., Wilson J.M. Safety and feasibiltiy of liver-directed ex vivo gene therapy for homozygous familial hypercholesteromia. Ann. Surg. 225(4):1997;442-443.
53. Richards C.A., Austin E.A., Huber B.E. Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy. Hum. Gene Ther. 6:1995;881-893.
54. Riddell S.R., Elliott M., Lewinsohn D.A., Gilbert M.J., Wilson L., Manley S.A.et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 2:1996;216-223.
55. Robinson D., Elliot J.F., Chang L.J. Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 Tat. Gene Ther. 2:1995;269-278.
56. Russell S.J., Hawkins R.E., Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res. 21:1993;1081-1085.
57. Salmons B., Günzburg W.H. Targeting of retroviral vectors for gene therapy. Hum. Gene Ther. 4:1993;129-141.
58. Schnierle B.S., Moritz D., Jeschke M., Groner B. Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles. Gene Ther. 3:1996;334-342.
59. Schnierle B.S., Groner B. Retroviral targeted delivery. Gene Ther. 3:1996;1069-1073.
60. Somia N.V., Zoppe M., Verma I.M. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc. Natl. Acad. Sci. USA. 92:1995;7570-7574.
61. Takeuchi Y., Cosset F.L., Lachmann P.J., Okada H., Weiss R.A., Collins M.K.L. Type C retrovirus inactivation by human complement is determined by both the viral genome and producer cell. J. Virol. 68:1993;8001-8007.
62. Valsesia-Wittmann S., Drynda A., Deleage G., Umailley M., Danos O., Verdier G., Cosset F.L. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J. Virol. 68:1994;4609-4619.
63. Valsesia-Wittmann S., Morling F.J., Nilson B.H., Takeuchi Y., Russel S.J., Cosset F.L. Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J. Virol. 70:1996;2059-2064.
64. Vile R.G., Diaz R.M., Miller N., Mitchell S., Russell S.J. Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology. 214:1995;307-313.
65. Wang X.S., Yoder M.C., Zhou S.Z., Srivastava A. Parvovirus B19 promoter at map unit 6 confers autonomous replication competence and erythroid specificity to adeno-associated virus 2 in primary human hematopoietic cells. Proc. Natl. Acad. Sci. USA. 92:1995;12416-12420.
66. Wiertz, E.J.H.J., Tortorella, D., Bogyo, M., Yu, J., Mothes, W., Jones, T.R., Rapoport, T.A., Ploegh, H.L., 1996a. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384, 432-438.
67. Wiertz, E.J.H.J., Jones, T.R., Sun, L., Bogyo, M., Geuze, H.J., Ploegh, H.L., 1996b. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84, 769-779.
68. Wold W.S., Tollefson A.E., Hermiston T.W. E3 transcription unit of adenovirus. Curr. Top. Microbiol. Immunol. 199:1995;237-274.
69. York I.A., Roop C., Andrews D.W., Riddell S.R., Graham F.L., Johnson D.C. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell. 77:1994;525-535.
70. Zhou S.Z., Li Q., Stamatoyannopoulos G., Srivastava A. Adeno-associated virus 2-mediated transduction and erythroid cell-specific expression of human β-globin gene. Gene Ther. 3:1996;223-229.
71. Zufferey R., Nagy D., Mandel R.J., Naldini L., Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotech. 15:1997;871-875.